Your browser is no longer supported. Please, upgrade your browser.
ILMN Illumina, Inc. daily Stock Chart
Illumina, Inc.
IndexS&P 500 P/E34.43 EPS (ttm)5.02 Insider Own0.60% Shs Outstand146.87M Perf Week0.24%
Market Cap25.37B Forward P/E39.76 EPS next Y4.35 Insider Trans-14.05% Shs Float145.00M Perf Month-2.61%
Income740.10M PEG2.45 EPS next Q0.69 Inst Own96.30% Short Float2.60% Perf Quarter-1.45%
Sales2.42B P/S10.46 EPS this Y0.90% Inst Trans0.63% Short Ratio3.84 Perf Half Y8.14%
Book/sh17.47 P/B9.89 EPS next Y19.76% ROA17.30% Target Price178.13 Perf Year14.17%
Cash/sh12.11 P/C14.27 EPS next 5Y14.07% ROE32.70% 52W Range119.37 - 189.48 Perf YTD34.92%
Dividend- P/FCF49.31 EPS past 5Y38.00% ROI14.00% 52W High-8.83% Beta0.84
Dividend %- Quick Ratio3.10 Sales past 5Y17.80% Gross Margin67.50% 52W Low44.72% ATR3.67
Employees5500 Current Ratio3.50 Sales Q/Q4.60% Oper. Margin21.30% RSI (14)47.27 Volatility1.62% 2.20%
OptionableYes Debt/Eq0.41 EPS Q/Q313.40% Profit Margin30.50% Rel Volume1.44 Prev Close171.97
ShortableYes LT Debt/Eq0.41 EarningsAug 01 AMC Payout0.00% Avg Volume980.74K Price172.75
Recom2.60 SMA20-1.33% SMA50-1.92% SMA2007.83% Volume1,411,420 Change0.45%
Apr-26-17Reiterated Cantor Fitzgerald Neutral $155 → $170
Mar-20-17Upgrade Leerink Partners Mkt Perform → Outperform
Feb-01-17Reiterated UBS Buy $180 → $185
Jan-18-17Initiated Deutsche Bank Hold $160
Jan-10-17Upgrade BofA/Merrill Neutral → Buy
Jan-06-17Upgrade CL King Neutral → Buy
Dec-07-16Reiterated Morgan Stanley Underweight $115 → $100
Nov-10-16Resumed Leerink Partners Mkt Perform
Nov-02-16Downgrade First Analysis Sec Equal-Weight → Underweight $130 → $116
Oct-11-16Reiterated Cantor Fitzgerald Hold $165 → $155
Oct-11-16Reiterated Canaccord Genuity Hold $165 → $136
Oct-11-16Downgrade Citigroup Buy → Neutral
Aug-22-16Downgrade CL King Buy → Neutral
Jul-27-16Reiterated Mizuho Neutral $138 → $148
Jul-05-16Downgrade Morgan Stanley Equal-Weight → Underweight $130 → $110
Jun-22-16Initiated CL King Buy
May-04-16Reiterated Stifel Buy $215 → $160
May-04-16Reiterated Mizuho Neutral $150 → $138
May-04-16Reiterated Canaccord Genuity Hold $160 → $140
May-03-16Reiterated UBS Buy $210 → $180
Jul-21-17 07:15AM  7 Near-Monopolies That Are Perfectly Legal in America Motley Fool
Jul-14-17 03:04PM  ETFs with exposure to Illumina, Inc. : July 14, 2017 Capital Cube
Jul-12-17 06:00AM  6 Growth Stocks That Will Outlast a Bear Market Investopedia
Jul-11-17 06:30AM  Illumina to Announce Second Quarter 2017 Financial Results on Tuesday, August 1, 2017 Business Wire
Jul-05-17 04:22PM  3 Charts That Every Illumina, Inc. Investor Needs to See Motley Fool
Jul-03-17 10:56AM  Illumina Offers FDA-Approved NGS Cancer Companion Test Kit Zacks
Jul-01-17 06:44AM  Better Buy: Illumina, Inc. vs. Roche Holding Ltd. (ADR) Motley Fool
Jun-30-17 03:03PM  ETFs with exposure to Illumina, Inc. : June 30, 2017 Capital Cube
Jun-29-17 05:35PM  Illumina Announces FDA-approved Next-Generation Sequencing Cancer Companion Diagnostic Test Kit Business Wire
Jun-28-17 09:00AM  Adamas Appoints New Chief Financial Officer GlobeNewswire
Jun-26-17 03:01AM  Genomics England Adopts Illuminas BaseSpace Variant Interpreter for Cancer Business Wire
Jun-23-17 02:42PM  3 Stocks With Veeva Systems-Like Return Potential Motley Fool
08:16AM  Illumina, Inc. breached its 50 day moving average in a Bullish Manner : ILMN-US : June 23, 2017 Capital Cube
Jun-22-17 03:52PM  Illumina Shines as Another Biotech Winner
Jun-19-17 03:31PM  ETFs with exposure to Illumina, Inc. : June 19, 2017 Capital Cube
08:24AM  3 Most Wildly Overvalued Stocks in Biotech (At Least on Paper) Motley Fool
Jun-13-17 10:18AM  Coalition for Access to Prenatal Screening Announces Clinical Advisory Board PR Newswire
Jun-08-17 04:42PM  Illumina Inc. Stock History: The Genomic-Sequencing Leader's Path to Success Motley Fool
01:40PM  ETFs with exposure to Illumina, Inc. : June 8, 2017 Capital Cube
10:26AM  SHAREHOLDER ALERT: Levi & Korsinsky, LLP Files Amended Complaint Against Illumina, Inc. and Senior Officers Business Wire
Jun-07-17 03:43PM  Exact Sciences Corporation: The Bear Case From a Bull Motley Fool
Jun-06-17 08:39AM  Illumina, Inc. :ILMN-US: Earnings Analysis: Q1, 2017 By the Numbers : June 6, 2017 Capital Cube
Jun-03-17 07:30AM  Grail passes early test in quest to find cancer in blood Reuters
May-31-17 04:42PM  3 Top Gene-Sequencing Stocks Poised for Solid Growth Motley Fool
01:00PM  Historically Strong Stocks in June Investopedia
May-30-17 06:30AM  Illumina to Webcast Live Presentation at the Goldman Sachs Global Healthcare Conference Business Wire
May-25-17 09:03AM  5 Top Healthcare Technology Trends That Could Make You Rich Motley Fool
May-23-17 07:22PM  Start-up Genome Medical is training experts to help you figure out what your genetic tests mean CNBC
May-22-17 11:24AM  Illumina CEO: When you invest in health research you actu... CNBC Videos
09:00AM  Illumina Names Mark Van Oene Chief Commercial Officer, Sales Leader Brings Genomics Expertise and Strong Commercial Leadership Experience to the Role Business Wire
May-15-17 05:20PM  Blood money: Peninsula liquid biopsy company gets $360M injection American City Business Journals
May-14-17 12:03PM  3 Best Stocks in Personalized Medicine Motley Fool
May-10-17 06:01PM  The Two Reasons Why Illumina Rose 8.3% In April Motley Fool
May-09-17 07:30AM  Cramer: These Sectors Look Bullish (Part III)
07:04AM  What Is Digital Health? Motley Fool
May-04-17 06:30AM  Illumina to Webcast Live Presentation at the Bank of America Merrill Lynch Health Care Conference Business Wire
May-02-17 09:42PM  Developments in Instagram, Amazon, Blockchain, Autonomous Cars, and Illumina Harvest Exchange
Apr-29-17 07:24AM  Edited Transcript of ILMN earnings conference call or presentation 25-Apr-17 9:00pm GMT Thomson Reuters StreetEvents
Apr-27-17 06:15PM  Top Research Reports for Today: CAT, T, LMT and DD Zacks
01:42PM  Pacific Biosciences of California Reports Q1 Loss Due to Higher Costs Motley Fool
01:10PM  Here's Why Pacific Biosciences of California Is Sliding Today Motley Fool
Apr-26-17 07:17PM  Cancer start-up Grail added one of Silicon Valley's best-known biotech VCs to its board CNBC
10:18AM  Illumina (ILMN) Posts In-line Earnings in Q1, Margins Down Zacks
Apr-25-17 06:22PM  Illumina Inc. Meets Earnings Expectations Thanks to Solid Service Revenue Growth Motley Fool
06:06PM  Chipotle, Wynn, Arconic Beat; Stryker, Illumina Guide Q2 Profit Low Investor's Business Daily
04:16PM  Illumina meets 1Q profit forecasts Associated Press
04:05PM  Illumina Reports Financial Results for First Quarter of Fiscal Year 2017 Business Wire
Apr-24-17 04:47PM  Top Stocks In Buy Zone Ahead Of Results: Investing Action Plan Investor's Business Daily
Apr-22-17 06:43AM  3 Things to Look for in Illumina's Q1 Results Motley Fool
Apr-21-17 08:51AM  Should You Sell llumina (ILMN) Before Earnings? Zacks
Apr-20-17 04:20PM  The Top Gene-Sequencing Stock to Buy in 2017 Motley Fool
Apr-17-17 09:32AM  Can Illumina (ILMN) Spring a Surprise this Earnings Season? Zacks
09:30AM  The Zacks Analyst Blog Highlights: Microsoft, BlackRock, Northrop Grumman, NVIDIA and Illumina Zacks
Apr-16-17 02:02PM  3 Big Reasons to Be Bullish on Biotech Stocks Motley Fool
Apr-13-17 02:49PM  Top Research Reports for Today: MSFT, BLK, NOC Zacks
08:58AM  Illumina (ILMN) Launches VeriSeq NIPT Solution in Europe Zacks
Apr-12-17 08:47AM  The Long Game In Life Sciences: $181B Fund Baillie Gifford Invests Big In Private Companies Forbes
Apr-11-17 06:30AM  Illumina to Announce First Quarter 2017 Financial Results on Tuesday, April 25, 2017 Business Wire
Apr-10-17 02:00AM  Illumina Launches the VeriSeq NIPT Solution in Europe Business Wire
Apr-05-17 08:03AM  Better Buy: Illumina Inc. vs. Roche Holding AG Motley Fool
08:03AM  Better Buy: Illumina Inc. vs. Roche Holding AG
Apr-04-17 08:29AM  Apple's Streaming Aspirations Not Enough to Get by Facebook: Challenge Update
08:29AM  Apple's Streaming Aspirations Not Enough to Get by Facebook: Challenge Update
Apr-03-17 04:57PM  Apple's Premium Streaming Aspirations Not Enough to Get by Facebook: Challenge Update
09:00AM  Illumina Advances the Use of Genomics in Precision Oncology, Donates Thousands of Somatic Interpretations to CIViC Business Wire
Apr-02-17 05:20PM  Apple Walks All Over Nike, Facebook and Illumina Square Off: Challenge Update
05:20PM  Apple Walks All Over Nike, Facebook and Illumina Square Off: Challenge Update
Apr-01-17 11:04AM  In Your 40s? 3 Stocks You Might Want to Buy Motley Fool
11:04AM  In Your 40s? 3 Stocks You Might Want to Buy at Motley Fool
Mar-31-17 08:30PM  Here Are Some of the Top Health Care Stocks in the First Quarter
08:30PM  Here Are Some of the Top Health Care Stocks in the First Quarter
11:52AM  Innovation ETF (ARKK) Hits New 52-Week High
Mar-30-17 03:37PM  Nike, Apple, Illumina and Facebook Take Last 4 Spots in TheStreet's Market Bracket Challenge
03:37PM  Nike, Apple, Illumina and Facebook Take Last 4 Spots in TheStreet's Market Bracket Challenge at TheStreet
10:46AM  Facebook Squanders Snap's Title Hopes, Nike Advances: Challenge Update
10:46AM  Facebook Squanders Snap's Title Hopes, Nike Advances: Challenge Update
Mar-28-17 09:00AM  Macrogen Leads Precision Medicine by Advancing the Realization of the "$100 Genome Age" Business Wire
Mar-21-17 03:42PM  Here's Why the Best Is Yet to Come for Illumina, Inc. Motley Fool
03:42PM  Here's Why the Best Is Yet to Come for Illumina, Inc. at Motley Fool
Mar-20-17 01:37PM  Heres What Analysts Had To Say About Sonic, Alphabet, Illumina, FireEye, and Shake Shack at Insider Monkey
06:45AM  Illumina upgraded by Leerink Partners
Mar-19-17 11:01AM  Is Trump Bad for Healthcare Stocks? These 4 Winners Don't Think So at Motley Fool
Mar-17-17 09:58AM  Why We're Excited About These 3 Top Stocks at Motley Fool
08:17AM  Illumina, Inc. breached its 50 day moving average in a Bearish Manner : ILMN-US : March 17, 2017
07:39AM  Why Did the Healthcare Sector Fall on March 16?
Mar-16-17 03:12PM  Stock market pares post-Fed bounce as health care, utilities slump at MarketWatch
Mar-14-17 03:02PM  How You Can Profit From the Next Big Thing in Healthcare at Motley Fool
Mar-13-17 10:57AM  17 Year CIO Veteran Learns New Tricks As Illumina's CIO at Forbes
Mar-12-17 03:02PM  3 Huge Healthcare Trends and How to Invest in Them (Hint: One Is Marijuana) at Motley Fool
Mar-09-17 06:31PM  5 Stocks With Promising, Amazon-like Growth Potential at Motley Fool
Mar-08-17 09:24AM  1 Huge Reason to Buy Illumina, Inc. Stock Now at Motley Fool
03:52AM  CORRECTING and REPLACING Munich Leukemia Laboratory Selects IBM Watson and Illumina for Research Collaboration to Advance Diagnostics and Develop Personalized Treatment Tools for Leukemia & Lymphoma Business Wire
Mar-07-17 06:18PM  Opko Health subsidiary launches prenatal testing tool at
12:11PM  Drug innovators will continue to do well: Isaly
08:21AM  What Illumina's and Bristol-Myers Squibb's Latest GRAIL Moves Mean for Investors at Motley Fool
08:00AM  OPKO Subsidiary GenPath Womens Health Announces the Availability of ClariTest GlobeNewswire
Mar-01-17 08:06AM  ILLUMINA INC Files SEC form 8-K, Other Events
Feb-28-17 09:30AM  OPKO Healths GeneDx Announces Participation in Illuminas iHope Program on International Rare Disease Day GlobeNewswire
09:00AM  Illumina Announces the iHope Network, an Expansion of Its iHope Philanthropic Clinical Whole Genome Sequencing Program Business Wire
08:01AM  3 Top Healthcare Stocks to Buy Now at Motley Fool
Illumina, Inc. provides sequencing and array-based solutions for genetic analysis. The company's sequencing by synthesis technology provides researchers with various applications and the ability to sequence mammalian genomes. It also offers arrays for a range of deoxyribonucleic acid and RNA analysis applications, including single nucleotide polymorphism genotyping, copy number variations analysis, gene expression analysis, and methylation analysis, as well as allow for the detection of known genetic markers on a single array. In addition, the company provides various library preparation and sequencing kits to simplify workflows and accelerate analysis; and genome sequencing, genotyping, and non-invasive prenatal testing services. It serves genomic research centers, academic institutions, government laboratories, and hospitals, as well as pharmaceutical, biotechnology, agrigenomics, commercial molecular diagnostic laboratories, and consumer genomics companies. The company markets and distributes its products directly to customers in North America, Europe, Latin America, and the Asia-Pacific region, as well as through life-science distributors. It has collaboration agreements with IBM Watson Health to access genome data interpretation by integrating Watson for genomics into Illumina's BaseSpace Sequence Hub and tumor sequencing process; and NRGene to develop new molecular breeding tools for cattle to support global food production. The company also has a co-development agreement with Munich Leukemia Laboratory GmbH and IBM Watson Health to build a cognitive technology prototype to help researchers improve leukemia treatment. Illumina, Inc. was founded in 1998 and is headquartered in San Diego, California.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
FLATLEY JAY TDirectorJul 18Option Exercise70.8215,0001,062,300534,176Jul 20 07:37 PM
FLATLEY JAY TDirectorJul 18Sale170.7715,0002,561,565519,176Jul 20 07:37 PM
Stapley MarcEVP & Chief Administrative OfcJul 14Sale173.562,000347,12338,641Jul 17 08:34 PM
OSTADAN OMEADEVP Ops, Products, StrategyJul 07Sale172.731,672288,80526,242Jul 11 07:29 PM
FLATLEY JAY TDirectorJul 05Option Exercise70.8215,0001,062,300534,176Jul 07 06:10 PM
FLATLEY JAY TDirectorJul 05Sale172.9215,0002,593,830519,176Jul 07 06:10 PM
Dadswell CharlesSr VP & General CounselJul 03Sale174.2414525,26510,646Jul 05 07:13 PM
Bouchard MichelChief Accounting OfficerJun 23Sale185.0024645,51018,893Jun 23 07:25 PM
FLATLEY JAY TDirectorJun 22Option Exercise70.825,000354,100524,176Jun 22 06:49 PM
FLATLEY JAY TDirectorJun 22Sale180.005,000900,000519,176Jun 22 06:49 PM
FLATLEY JAY TDirectorJun 20Option Exercise70.8215,0001,062,300534,176Jun 22 06:49 PM
FLATLEY JAY TDirectorJun 20Sale177.6115,0002,664,120519,176Jun 22 06:49 PM
Stapley MarcEVP & Chief Administrative OfcJun 12Sale170.852,000341,69940,641Jun 14 08:19 PM
Bouchard MichelChief Accounting OfficerJun 08Sale178.9124644,01219,139Jun 09 02:09 PM
FLATLEY JAY TDirectorJun 06Option Exercise36.3020,000726,000539,176Jun 08 04:43 PM
FLATLEY JAY TDirectorJun 06Sale180.2420,0003,604,878519,176Jun 08 04:43 PM
Dadswell CharlesSr VP & General CounselJun 05Sale184.7514526,78910,791Jun 07 05:26 PM
FLATLEY JAY TDirectorJun 02Sale182.001,720313,0402,680Jun 02 08:07 PM
FLATLEY JAY TDirectorJun 01Sale179.001,600286,4004,400Jun 02 08:07 PM
BRADBURY DANIELDirectorMay 25Option Exercise71.0960042,65415,924May 26 06:25 PM
ARNOLD FRANCESDirectorMay 25Sale174.77825144,1858,816May 26 06:22 PM
BRADBURY DANIELDirectorMay 25Sale173.61600104,16715,324May 26 06:25 PM
FLATLEY JAY TDirectorMay 23Option Exercise36.3015,000544,500534,176May 25 06:42 PM
FLATLEY JAY TDirectorMay 23Sale175.5315,0002,632,983519,176May 25 06:42 PM
BOWMAN A BLAINEDirectorMay 10Option Exercise75.662,300174,01818,004May 12 07:14 PM
BOWMAN A BLAINEDirectorMay 10Sale181.612,300417,71015,704May 12 07:14 PM
FLATLEY JAY TDirectorMay 09Option Exercise36.3020,000726,000539,176May 11 05:53 PM
Bouchard MichelChief Accounting OfficerMay 09Sale184.685,7401,060,03519,385May 10 08:08 PM
FLATLEY JAY TDirectorMay 09Sale184.1420,0003,682,718519,176May 11 05:53 PM
OSTADAN OMEADEVP Ops, Products, StrategyMay 08Sale186.101,672311,15927,914May 10 04:20 PM
Dadswell CharlesSr VP & General CounselMay 03Sale187.071,609300,99610,936May 05 07:52 PM
BOWMAN A BLAINEDirectorApr 12Option Exercise75.663,000226,98018,704Apr 13 06:40 PM
BOWMAN A BLAINEDirectorApr 12Sale172.723,000518,15115,704Apr 13 06:40 PM
BRADBURY DANIELDirectorApr 07Option Exercise71.0960042,65417,065Apr 11 08:16 PM
BRADBURY DANIELDirectorApr 07Sale172.79600103,67516,465Apr 11 08:16 PM
OSTADAN OMEADEVP Ops, Products, StrategyMar 24Sale170.001,672284,24029,586Mar 28 07:05 PM
BRADBURY DANIELDirectorMar 21Option Exercise71.0960042,65417,065Mar 23 02:14 PM
BRADBURY DANIELDirectorMar 21Sale163.5660098,13416,465Mar 23 02:14 PM
BOWMAN A BLAINEDirectorMar 08Option Exercise75.663,000226,98018,704Mar 10 07:41 PM
BOWMAN A BLAINEDirectorMar 08Sale164.883,000494,63315,704Mar 10 07:41 PM
BRADBURY DANIELDirectorFeb 17Option Exercise71.0960042,65417,065Feb 21 09:05 PM
BRADBURY DANIELDirectorFeb 17Sale162.8060097,67716,465Feb 21 09:05 PM
Bouchard MichelChief Accounting OfficerFeb 15Option Exercise0.002,625025,292Feb 17 08:11 PM
deSouza Francis APresident and CEOFeb 15Option Exercise0.0014,318082,523Feb 17 09:05 PM
Stapley MarcEVP & Chief Administrative OfcFeb 15Option Exercise0.008,438044,423Feb 17 08:51 PM
Ronaghi MostafaSr VP & CTOFeb 15Option Exercise0.007,032067,922Feb 17 08:45 PM
FLATLEY JAY TDirectorFeb 15Option Exercise0.0028,5100527,236Feb 17 08:37 PM
Dadswell CharlesSr VP & General CounselFeb 15Option Exercise0.007,032014,699Feb 17 08:22 PM
OSTADAN OMEADEVP Ops, Products, StrategyFeb 15Option Exercise0.008,438033,009Feb 17 08:16 PM
OSTADAN OMEADEVP Ops, Products, StrategyFeb 13Sale163.102,173354,41624,571Feb 15 07:42 PM
BOWMAN A BLAINEDirectorFeb 08Option Exercise70.193,000210,56018,704Feb 10 03:55 PM
BOWMAN A BLAINEDirectorFeb 08Sale162.743,000488,23115,704Feb 10 03:55 PM
Dadswell CharlesSr VP & General CounselFeb 06Sale161.2657292,2417,592Feb 08 07:39 PM
OSTADAN OMEADEVP Ops, Products, StrategyFeb 02Sale160.411,104177,09326,586Feb 06 08:17 PM
OSTADAN OMEADEVP Ops, Products, StrategyJan 30Sale160.9025941,67327,690Jan 31 07:31 PM
OSTADAN OMEADEVP Ops, Products, StrategyJan 19Sale160.3537860,61228,662Jan 19 05:56 PM
OSTADAN OMEADEVP Ops, Products, StrategyJan 17Sale160.002,000320,00029,040Jan 19 05:56 PM
BOWMAN A BLAINEDirectorJan 11Option Exercise42.823,000128,46018,704Jan 13 07:05 PM
BOWMAN A BLAINEDirectorJan 11Sale162.893,000488,65815,704Jan 13 07:05 PM
Dadswell CharlesSr VP & General CounselJan 10Sale161.6011618,7468,420Jan 12 09:36 PM
BRADBURY DANIELDirectorJan 04Option Exercise71.0960042,65417,065Jan 06 06:59 PM
BRADBURY DANIELDirectorJan 04Sale135.0160081,00816,465Jan 06 06:59 PM
OSTADAN OMEADEVP Ops, Products, StrategyDec 15Sale126.162,000252,32031,040Dec 19 08:08 PM
BRADBURY DANIELDirectorDec 12Option Exercise71.0960042,65417,065Dec 14 08:09 PM
BRADBURY DANIELDirectorDec 12Sale123.4260074,05416,465Dec 14 08:09 PM
OSTADAN OMEADEVP Ops, Products, StrategyDec 08Sale121.633,000364,89052,988Dec 09 04:18 PM
OSTADAN OMEADEVP Ops, Products, StrategyDec 01Sale133.303,000399,90051,492Dec 05 06:41 PM
BRADBURY DANIELDirectorNov 14Option Exercise71.0960042,65417,065Nov 15 06:14 PM
BRADBURY DANIELDirectorNov 14Sale136.3460081,80316,465Nov 15 06:14 PM
BRADBURY DANIELDirectorOct 07Option Exercise71.0960042,65417,065Oct 11 08:35 PM
BRADBURY DANIELDirectorOct 07Sale184.36600110,61316,465Oct 11 08:35 PM
Dadswell CharlesSr VP & General CounselOct 04Sale182.3811621,15639,900Oct 06 05:32 PM
EPSTEIN ROBERT SDirectorSep 20Sale174.2930052,2876,924Sep 21 06:56 PM
Stapley MarcEVP & Chief Administrative OfcSep 15Sale172.871,270219,54332,746Sep 16 08:07 PM
BRADBURY DANIELDirectorSep 14Option Exercise71.0960042,65417,065Sep 16 07:58 PM
BRADBURY DANIELDirectorSep 14Sale171.25600102,74816,465Sep 16 07:58 PM
Dadswell CharlesSr VP & General CounselSep 06Sale168.0111619,48940,016Sep 08 07:58 PM
FLATLEY JAY TDirectorAug 23Option Exercise36.3020,000726,000508,061Aug 25 08:43 PM
FLATLEY JAY TDirectorAug 23Sale172.9920,0003,459,877488,061Aug 25 08:43 PM
EPSTEIN ROBERT SDirectorAug 22Sale170.2730051,0817,224Aug 23 08:19 PM
EPSTEIN ROBERT SDirectorAug 22Sale170.2730051,0817,224Aug 24 07:52 PM
BRADBURY DANIELDirectorAug 17Option Exercise71.0960042,65417,065Aug 18 08:31 PM
BRADBURY DANIELDirectorAug 17Sale168.42600101,05316,465Aug 18 08:31 PM
FLATLEY JAY TDirectorAug 15Option Exercise36.3010,000363,000498,061Aug 16 06:56 PM
FLATLEY JAY TDirectorAug 15Sale170.0010,0001,700,000488,061Aug 16 06:56 PM
WHITFIELD ROY ADirectorAug 12Option Exercise42.824,000171,2806,853Aug 15 06:03 PM
WHITFIELD ROY ADirectorAug 12Sale167.224,000668,8802,853Aug 15 06:03 PM
FLATLEY JAY TDirectorAug 09Option Exercise36.3010,000363,000498,061Aug 10 09:40 PM
FLATLEY JAY TDirectorAug 09Sale165.9710,0001,659,650488,061Aug 10 09:40 PM
Dadswell CharlesSr VP & General CounselAug 04Sale164.6311619,09740,132Aug 08 06:36 PM
FLATLEY JAY TDirectorAug 01Option Exercise36.3010,000363,000498,061Aug 02 07:27 PM
FLATLEY JAY TDirectorAug 01Sale170.0010,0001,700,000488,061Aug 02 07:27 PM
Dadswell CharlesSr VP & General CounselJul 27Sale155.008,6321,337,96040,248Jul 28 07:44 PM
FLATLEY JAY TDirectorJul 26Option Exercise36.3010,000363,000498,061Jul 28 07:39 PM
FLATLEY JAY TDirectorJul 26Sale150.0010,0001,500,000488,061Jul 28 07:39 PM